Ultimate
Predictability

genOway offers preclinical models and solutions to bio-pharmaceutical and academic researchers for ultimate predictability.
Discover how Macomics tested the efficacy of their mAb with genO-BRGSF-HIS mice
Learn more
Safety testing: choose genO-BRGSF-HIS mice instead of PBMC-reconstituted models
Learn more
Watch how the humanized genO-hFcγR mouse better predicts antibody efficacy and safety
Learn more

Ensuring the ultimate predictability of your research

At genOway, we recognize the crucial role that preclinical research plays in the success of new therapies in clinical settings. Our team of experts brings together decades of experience in designing genetically modified models and a profound understanding of biological physiology to provide unmatched preclinical solutions.

Our collaborative approach, rooted in a deep understanding of your specific needs and complemented by our expertise, strives to define the best solution to predict the success of your research. Join us on a journey of scientific advancement for the benefit of human health.

  • 28
    countries worldwide
  • 380
    academic institutions
  • 13
    EU projects
  • 170
    Life Sciences companies
  • 17
    of the Top 20 pharma

Catalog models

Explore our comprehensive catalog of preclinical models, featuring genetically modified mice, rats, and cell lines. All our models were designed and validated with the highest standards of excellence to ensure the ultimate predictability of your research.

Learn more

Customized models

Explore our service for creating genetically modified mouse, rat, and cell line models perfectly adapted to answer your scientific questions. With an in-depth understanding of your needs, our team of scientific experts, committed to your side, will accompany you throughout this journey.

Learn more
Our latest resources and publications
Posters
Scientific Articles
Commentaries
Double humanized genO-hCD47/hSIRPα mouse model and MC38 cell line expressing human CD47 for efficacy and safety assessment of anti-CD47/SIRPα-targeting therapies

Humanized mice for anti-CD47/SIRPα-targeting therapies

Jun 2025
Human immune cell composition of TME depends on tumor cell line-derived xenograft subtype and tumor burden in genO-BRGSF-HIS mice

TME composition in genO-BRGSF-HIS mice

Jun 2025
(Oncodesign) Novel PSMA+ and FAP+ mouse models to support the development of novel molecular radiotherapy agents

New radiotherapy development with genO-BRGSF

May 2025
Show all posters
PET-based immunomapping of intratumoral CD4+ cells to monitor acquired resistance to checkpoint inhibitors

Sci Adv

2025
Consolidation of cell‑ECM adhesion through direct talin‑mediated actin linkage is essential for mouse embryonic morphogenesis

Commun Biol

2025
Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival

Nat Commun

2025
Show all scientific articles
Targeted immunotherapy against autoreactive B cells in autoimmune diseases

T-cell engagers in immunotherapies

10 min read
-
Mar 2025
A radiolabeled VISTA antibody for imaging VISTA expression

hVISTA - antibodies & PET imaging

7 min read
-
Oct 2024
New CD4-specific minibodies to predict cancer treatment outcomes

CD4 for cancer treatment outcomes

5 min read
-
Oct 2024
Show all commentaries